Acumen Pharmaceuticals is developing an Alzheimer’s disease drug that it believes offers advantages compared to other approaches—including the recently approved Biogen therapy. A small clinical trial ...

Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technology ...

Acumen Pharmaceuticals has set the terms for its IPO, teeing it up to raise around $125 million to take an antibody against amyloid-beta oligomers to the end of phase 2 in Alzheimer’s disease.

Forbes contributors publish independent expert analyses and insights. Anne Field covers impact entrepreneurship and impact investing. A few years ago, Acumen, the pioneering patient capital impact ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual Alzheimer’s Association International Conference. ACU193 is an anti-beta amyloid with a unique ...

Two years removed from an IPO, Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) looks like it made a good decision to go public. Shares of the Charlottesville, Virginia-based biotechnology company ...

- Poster presentation showcases method used to develop a first-of-its-kind assay to assess sabirnetug’s binding to amyloid beta oligomers (AβOs) in Alzheimer’s disease - Company on track to initiate ...

In a company, a manager seen as having general business acumen is one who consistently exercises sound judgment – the results of his decisions are most often favorable. Those he works with would say ...

Forbes contributors publish independent expert analyses and insights. Melissa Houston covers financial issues that affect women in business. Being an entrepreneur involves a commitment to continuous ...